Inogen (INGN) Upgraded at BidaskClub

BidaskClub upgraded shares of Inogen (NASDAQ:INGN) from a strong sell rating to a sell rating in a research note released on Wednesday morning.

A number of other research analysts also recently weighed in on the company. Needham & Company LLC raised their price target on Inogen to $280.00 and gave the company a strong-buy rating in a research note on Monday, November 26th. ValuEngine downgraded Inogen from a buy rating to a hold rating in a research note on Wednesday, November 7th. Zacks Investment Research upgraded Inogen from a hold rating to a buy rating and set a $290.00 price target for the company in a research note on Thursday, September 27th. Piper Jaffray Companies raised their price target on Inogen from $245.00 to $290.00 and gave the company an overweight rating in a research note on Wednesday, September 12th. Finally, Stifel Nicolaus set a $258.00 price target on Inogen and gave the company a buy rating in a research note on Tuesday, August 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and an average price target of $244.67.

INGN stock opened at $147.36 on Wednesday. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of 112.49, a P/E/G ratio of 2.80 and a beta of 1.56. Inogen has a twelve month low of $112.78 and a twelve month high of $287.79.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.21. The firm had revenue of $95.29 million during the quarter, compared to the consensus estimate of $90.94 million. Inogen had a return on equity of 18.91% and a net margin of 12.28%. The business’s revenue was up 38.0% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share. On average, equities research analysts predict that Inogen will post 2.1 EPS for the current year.

In other news, Director Ray Benjamin M. Anderson sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $246.22, for a total value of $246,220.00. Following the completion of the sale, the director now directly owns 1,989 shares of the company’s stock, valued at $489,731.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Raymond Huggenberger sold 10,500 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $282.57, for a total value of $2,966,985.00. Following the completion of the sale, the director now directly owns 8,797 shares of the company’s stock, valued at $2,485,768.29. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,500 shares of company stock valued at $9,008,475. Insiders own 5.29% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in INGN. Principal Financial Group Inc. lifted its position in shares of Inogen by 4.7% in the first quarter. Principal Financial Group Inc. now owns 146,433 shares of the medical technology company’s stock valued at $17,988,000 after buying an additional 6,622 shares during the last quarter. Xact Kapitalforvaltning AB lifted its position in shares of Inogen by 12.2% in the second quarter. Xact Kapitalforvaltning AB now owns 2,765 shares of the medical technology company’s stock valued at $515,000 after buying an additional 300 shares during the last quarter. Amalgamated Bank lifted its position in shares of Inogen by 15.8% in the second quarter. Amalgamated Bank now owns 2,874 shares of the medical technology company’s stock valued at $536,000 after buying an additional 393 shares during the last quarter. Meeder Asset Management Inc. lifted its position in shares of Inogen by 1,278.3% in the second quarter. Meeder Asset Management Inc. now owns 1,778 shares of the medical technology company’s stock valued at $331,000 after buying an additional 1,649 shares during the last quarter. Finally, Piedmont Investment Advisors LLC lifted its position in shares of Inogen by 9.8% in the second quarter. Piedmont Investment Advisors LLC now owns 4,059 shares of the medical technology company’s stock valued at $756,000 after buying an additional 361 shares during the last quarter. 96.94% of the stock is owned by institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Story: Does the discount rate affect the economy?

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit